Stryker Corporation is a leading medical technology company that specializes in designing, manufacturing, and marketing innovative products and services for healthcare professionals and patients. The company offers a diverse range of medical devices, including surgical equipment, orthopedic implants, neurotechnology, and surgery assistance products. Stryker focuses on advancing healthcare through cutting-edge technology and solutions that enhance patient care, improve surgical outcomes, and streamline hospital operations. With a commitment to innovation and quality, Stryker plays a pivotal role in the medical industry, helping healthcare providers deliver effective treatment and improve the quality of life for patients around the world. Read More
Shares of medical technology company Stryker (NYSE:SYK) jumped 4.1% in the afternoon session after analyst firm Raymond James upgraded the stock to "Outperform" from "Market Perform" and set a $418 price target.
As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence infrastructure captured the lion's share of investor attention, the healthcare sector has emerged as the unexpected powerhouse
As of December 26, 2025, Baxter International Inc. (NYSE: BAX) stands at a pivotal crossroads in its nearly century-long history. Long considered a defensive "blue-chip" staple of the healthcare sector, Baxter spent much of the early 2020s grappling with the massive debt from its $10.5 billion acquisition of Hillrom, supply chain fragilities exposed by the [...]
Portage, Michigan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its fourth quarter and full year 2025 on Thursday, January 29, 2026. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company’s fourth quarter and full year that ended December 31, 2025.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
New York, NY – December 17, 2025 – The Dow Jones Industrial Average (DJIA) has concluded December 2025 with a notable ascent, marking a period of robust performance that has seen the index reach new all-time record highs. This upward momentum, however, unfolds against a complex and often contradictory economic landscape, characterized
Despite recent pockets of volatility and "slips" in the U.S. stock market during late 2025, a robust corporate profit outlook is emerging as a powerful counter-narrative, fueling investor optimism and suggesting that still-higher prices for American equities may be on the horizon. While the Cboe Volatility Index (VIX) saw
December 11, 2025 – The U.S. stock market is currently witnessing a striking and arguably unprecedented divergence, as the Dow Jones Industrial Average (DJIA) continues its ascent to record highs, while the tech-heavy Nasdaq Composite grapples with a significant slump. This "Great Divergence" signals a profound recalibration of investor sentiment,
Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter.
Over the past six months, Stryker’s shares (currently trading at $350.50) have posted a disappointing 9% loss, well below the S&P 500’s 13.4% gain. This may have investors wondering how to approach the situation.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Stryker (NYSE:SYK) and its peers.
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Stryker’s third quarter was marked by broad-based demand and resilient procedural volumes across its business segments, with management highlighting sustained organic sales growth and margin discipline. CEO Kevin Lobo attributed the results to strong performance in both Orthopedics and MedSurg & Neurotechnology, particularly emphasizing the impact of high Mako robotic system installations and robust growth in Trauma, Vascular, and Instruments. Lobo noted that “procedure volumes are very healthy, which affects, obviously, our implants as well as our small capital,” and pointed to a solid U.S. environment for both product and capital spending. Despite some lingering supply chain disruptions in the Medical segment, Stryker’s leadership cited strong execution and order books as key drivers for the quarter.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
